drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous TCR-T)
drug_description
Autologous, gene-modified TCR-engineered T cells (TCR-T; T-Plex) expressing a high-affinity TCR specific for MAGE-A1 peptide presented by HLA-C*07:02; designed to recognize peptide–HLA on tumor cells and trigger TCR/CD3 signaling and cytotoxicity after lymphodepletion.
nci_thesaurus_concept_id
C201132
nci_thesaurus_preferred_term
Autologous Anti-MAGE-A1 TCR-engineered T-cells TSC-204-C0702
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that are engineered to express a T-cell receptor (TCR) specific for melanoma-associated antigen A1 (MAGE-A1) presented on human leukocyte antigen (HLA)-C*07:02, with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-MAGE-A1 TCR-engineered T-cells TSC-204-C0702 specifically recognize and bind to MAGE-A1 expressed on tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing MAGE-A1. MAGE-A1 is a tumor-associated antigen (TAA) overexpressed by a variety of cancer cell types.
drug_mesh_term
T-Lymphocytes, Transgenic
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a high-affinity TCR specific for the MAGE-A1 peptide presented by HLA-C*07:02. Binding to the peptide-HLA complex on tumor cells activates TCR/CD3 signaling and cytotoxic effector functions, resulting in selective killing of MAGE-A1-positive tumor cells (administered after lymphodepletion).
drug_name
TSC-204-C0702
nct_id_drug_ref
NCT05973487